Last reviewed · How we verify

NCT07514104

Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple Sclerosis

Completed NA Last updated 7 April 2026
What this trial tests

NA trial testing Extracorporeal Shock Wave Therapy (ESWT) in Multiple Sclerosis in 54 participants. Completed in 15 October 2025.

Timeline
1 July 2021
Primary endpoint
15 February 2025
15 October 2025

Quick facts

Lead sponsorFurkan Bilek
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment54
Start date1 July 2021
Primary completion15 February 2025
Estimated completion15 October 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Furkan Bilek

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis or Multiple Sclerosis (MS) - Relapsing-remitting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial aimed to investigate the efficacy of Extracorporeal Shock Wave Therapy (ESWT) on plantar somatosensory function, knee joint proprioception, and spatiotemporal gait parameters in individuals diagnosed with Multiple Sclerosis (MS). The study included participants with a spasticity level below 1+, with the intervention group receiving ESWT three times per week over a 6-week period. To evaluate sensory changes, light touch thresholds were measured at six plantar sites-the heel, medial longitudinal arch, 1st and 5th metatarsal heads, and the 1st and 5th toes-using the Semmes-Weinstein monofilament kit. Additionally, two-point discrimination was assessed at the heel, and vibration duration was measured at the metatarsal heads using a 128 Hz tuning fork. Proprioception was quantified via the active knee joint reposition test in a closed kinetic chain position, measuring the absolute angular error at a 60° target angle. Postural stability and dynamic gait were objectively analyzed using the Win-Track platform and a reliable 3-step protocol to record parameters such as gait cycle duration, step length, cadence, and maximum plantar pressure. Static balance was further evaluated by recording the percentage of body weight transferred to each foot. By targeting both mechanoreceptor sensitivity and joint position sense, this 6-week ESWT intervention seeks to enhance the overall functional mobility and stability of MS patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Extracorporeal Shock Wave Therapy (ESWT)

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07514104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing